ST. HELIER, Jersey–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24NVCR&src=ctag" target="_blank"gt;$NVCRlt;/agt; lt;a href="https://twitter.com/hashtag/Jefferies?src=hash" target="_blank"gt;#Jefferieslt;/agt;–Novocure (NASDAQ: NVCR) announced today that Bill Doyle, Novocure’s
Executive Chairman, will participate in the Jefferies 2019 Global
Healthcare Conference on June 4, 2019, in New York City. Mr. Doyle’s presentation
will begin at 9 a.m. EDT and will be followed by a Q&A session. Mr.
Doyle will also participate in one-on-one meetings with investors
throughout the day.
A live audio webcast of the presentation can be accessed from the
Investor Relations page of Novocure’s website, www.novocure.com/investor-relations,
and will be available for replay for at least 14 days following the
events.
Novocure’s corporate presentation is updated periodically, and the
current presentation can be accessed from the Investor Relations page of
Novocure’s website, www.novocure.com/investor-relations.
About Novocure
Novocure is an oncology company developing a profoundly different cancer
treatment utilizing a proprietary therapy called Tumor Treating Fields,
the use of electric fields tuned to specific frequencies to disrupt
solid tumor cancer cell division. Novocure’s commercialized product is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed clinical trials investigating Tumor Treating
Fields in brain metastases, non-small cell lung cancer, pancreatic
cancer, ovarian cancer, liver cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, clinical trial progress,
timing of clinical milestones, development of potential products,
interpretation of clinical results, prospects for regulatory submission
and approval, manufacturing development and capabilities, market
prospects for its products, coverage, collections from third-party
payers and other statements regarding matters that are not historical
facts. You may identify some of these forward-looking statements by the
use of words in the statements such as “anticipate,” “estimate,”
“expect,” “project,” “intend,” “plan,” “believe” or other words and
terms of similar meaning. Novocure’s performance and financial results
could differ materially from those reflected in these forward-looking
statements due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K filed
on February 28, 2019, with the U.S. Securities and Exchange Commission.
Given these risks and uncertainties, any or all of these forward-looking
statements may prove to be incorrect. Therefore, you should not rely on
any such factors or forward-looking statements. Furthermore, Novocure
does not intend to update publicly any forward-looking statement, except
as required by law. Any forward-looking statements herein speak only as
of the date hereof. The Private Securities Litigation Reform Act of 1995
permits this discussion.
Contacts
Media and Investor Contact:
Ashley Cordova
acordova@novocure.com
212-767-7558